Lauren Halby, MD
Family Medicine · Colorado Springs, CONPI 1801848759
Payments from drug & device makers
Across 226 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$488
- Amgen$420
- Novo Nordisk$357
- AstraZeneca$347
- Pfizer$343
- Lilly USA, LLC$265
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,073100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 23 | $488 |
| Amgen(2 entities) | 21 | $420 |
| Novo Nordisk | 22 | $357 |
| AstraZeneca | 20 | $347 |
| Pfizer | 22 | $343 |
| Lilly USA, LLC | 25 | $265 |
| Astellas Pharma US Inc | 10 | $211 |
| Inspire Medical Systems, Inc. | 4 | $195 |
| GSK | 9 | $192 |
| Johnson & Johnson(2 entities) | 10 | $149 |
| Exact Sciences | 6 | $123 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $102 |
| Sanofi-aventis U.S. LLC | 4 | $91 |
| Boehringer Ingelheim | 5 | $82 |
| Jazz Pharmaceuticals Inc. | 2 | $61 |
| Idorsia Pharmaceuticals US Inc | 4 | $56 |
| Merck | 4 | $56 |
| Aimmune Therapeutics, Inc. | 2 | $52 |
| Novartis | 2 | $44 |
| Radius Health, Inc. | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Cranial Technologies, Inc | 2 | $34 |
| Insulet Corporation | 2 | $30 |
| Bioventus LLC | 1 | $26 |
| Krystal Biotech Inc | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Boston Scientific | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Seqirus USA Inc | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Assertio Therapeutics, Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| MDD US Operations, LLC | 1 | $14 |
| Bayer | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$106
How this compares
$4,073 in reported general payments places this provider in the 90th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 54 | $45,527 |
| JardianceEmpagliflozin | 37 | $34,739 |
| RybelsusSemaglutide | 17 | $26,662 |
| XareltoRivaroxaban | 19 | $26,661 |
| MounjaroTirzepatide | 12 | $11,742 |
| FarxigaDapagliflozin Propanediol | 13 | $9,778 |
| MyrbetriqMirabegron | 14 | $9,145 |
| Bupropion XlBupropion Hcl | 62 | $1,773 |
| Levothyroxine Sodium | 163 | $1,616 |
| Rosuvastatin Calcium | 115 | $1,565 |
| SynthroidLevothyroxine Sodium | 14 | $1,524 |
| Estradiol | 30 | $1,292 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $1,244 |
| Gabapentin | 60 | $1,214 |
| Atorvastatin Calcium | 151 | $1,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $343 | $45,52754 claims |
| Boehringer IngelheimJardiance | $82 | $34,73937 claims |
| Novo NordiskRybelsus | $357 | $26,66217 claims |
| Johnson & JohnsonXarelto | $149 | $26,66119 claims |
| Lilly USA, LLCMounjaro | $265 | $11,74212 claims |
| AstraZenecaFarxiga | $347 | $9,77813 claims |
| Astellas Pharma US IncMyrbetriq | $211 | $9,14514 claims |
| AbbVieSynthroid | $488 | $1,52414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Colorado Springs
- Ripley HollisterColorado Springs$5.5M
- Matthew YoungColorado Springs$270K
- Lawrence AndrewsColorado Springs$102K
- Jeffrey SnyderColorado Springs$31K
- Elizabeth EricksonColorado Springs$31K
- Daniel RohwederColorado Springs$21K
- Stephen FarkasColorado Springs$20K
- Max NevarezColorado Springs$15K
- Clint FlanaganDacono$7.6M
- Larry OdekirkCastle Rock$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.